Anjalee Khemlani

    Senior Reporter

    Anjalee Khemlani is a reporter at Yahoo Finance covering all things business, with a focus on health care. Khemlani has previously worked for a variety of media organizations that include startup digital, legacy daily news, international broadcast and local radio. Her most recent position was as a managing editor of ROI-NJ in New Jersey.

  • Moody's says will be 'many years' before big AI impacts are seen in healthcare, pharma

    Moody's says pharma and medical device companies are most likely to see the earliest benefits from adopting AI technology.

  • UnitedHealth Group top pick despite cyberattack and DOJ setbacks: BofA

    UnitedHealth Group's recent cyberattack and DOJ probe are unlikely to be long-term headwinds, according to a BoA analyst.

  • UnitedHealth's cyberattack should be a 'wake-up call' for healthcare

    UnitedHealth Group faced a cyberattack that froze an important subsidiary in the healthcare ecosystem.

  • Communication is key in managing cyberattack: Optum CEO

    UnitedHealth Group's Change Healthcare subsidiary is expected to have a "material update" as early as Tuesday following a major ransomware attack that's now on its fifth straight day and stalling care around the country.

  • Moderna CEO: 2024 is year of growth, with 2023 transition in rearview

    Moderna posted strong results despite investors assuming a loss for the year.

  • Novavax resolves Gavi dispute over COVID-19 vaccines

    Novavax has resolved a potentially expensive battle with Gavi, opening up a pathway for the company to get out of the red.

  • CVS chief medical officer: 'We are not looking to build the entire healthcare delivery ecosystem'

    CVS is bullish on its health services outlook, even as the broader industry faces pressure.

  • CEO Bertolini: 2024 is the year Oscar will be profitable

    Health insurer Oscar Health says it's going to be profitable in 2024.

  • GLP-1s: 'We're investing behind this in a big way,' says Amgen CFO

    Amgen is focused on price declines while it looks to fill out its portfolio and chase the new obesity market.

  • Eli Lilly CFO: Weight-loss drug demand will outstrip GLP-1 supply through 2024

    Eli Lilly blew past Wall Street estimates for its latest earnings but faces pressure ahead to deliver strong results for the year.

  • The US government has backed 'food as medicine' movement, but does it have staying power?

    The US Health Department held a conference to discuss the federal government's efforts to help address food insecurity.

  • Seagen acquisition will give Pfizer 'anchor asset' Wall Street desires: Pfizer CEO Bourla

    Pfizer beat earnings expectations, but Wall Street is still waiting to see how it pulls out of waning COVID demand and boosts its pipeline with stronger assets to plug a patent cliff at the end of the decade.

  • Novo Nordisk earnings: 'I could smile a long time over results like this,' says CFO Knudsen

    Novo Nordisk beat Wall Street estimates for 2023, but its 2024 outlook is what investors are keen on watching.

  • How a 'complex' Medicare Advantage market left Humana scrambling to start 2024

    Humana signaling rough waters ahead after pent-up demand caused the company to realize losses in its Medicare Advantage business in late 2023.

  • Why Wall Street no longer fears sprawling impact from the weight loss drug craze

    Obesity drugs, known as GLP-1s, continue to be all the rage in 2024. But doomsday predictions of long-term impact to other industries may be cooling.

  • Beyond the Ticker: Novo Nordisk

    The popularity of Novo Nordisk's (NVO) blockbuster obesity drug Wegovy, and diabetes drug Ozempic, for weight loss, was so great in 2023 that it has been credited with propping up the entire economy of Denmark. It is that impact and buzz that led Yahoo Finance to name Novo Nordisk its 2023 Company of the Year. Novo's gross profit in 2023 was nearly $26 billion, or almost a 27% increase year-over-year. And the stock is on a tear, up more than 50% in the past year. Let’s look at what started Novo’s boom with Beyond the Ticker, where we take a closer look at some of the company's biggest moments. 1923 Nordisk Insulinlaboratorium commercialized the production of insulin. 1925 Two employees broke away from Nordisk to form rival Novo Terapeutisk Laboratorium. 1982 Nordisk first established its presence in the United States. 1985 The NovoPen, the first insulin pen device, launched. 1989 Nordisk and Novo merged to become Novo Nordisk A/S, the world's largest producer of insulin. 2017 The FDA approved Ozempic for diabetes. 2021 The FDA approved Ozempic to treat obesity in diabetes patients. The FDA also approved Wegovy for weight loss in obese or overweight adults. These two products launched a new era in GLP-1s, which have been around since 2005. 2020 - present Novo has spent more than $7 billion on diabetes and obesity biotechs, fortifying its lead in the brand new obesity market. From tech giants to retail titans, Beyond the Ticker is a historical series that takes a deep dive into some of Wall Street's trending companies and how they transformed into the financial icons they are today. Check out more of our Beyond the Ticker series, and be sure to tune in to Yahoo Finance. Editor's note: This video was produced by Zach Faulds.

  • Rightway CEO talks Tyson Foods choosing his startup over CVS

    Tyson Foods (TSN) has announced that it will be dropping CVS' Caremark (CVS) as its pharmacy benefits manager and will be switching to Rightway. This is the second Fortune 100 company to drop CVS in the last year. Could shifts like these open up opportunities for smaller pharmacy benefit management companies? Jordan Feldman, Rightway CEO joins Yahoo Finance Live to discuss what makes the company stand out—and what the benefits landscape could look like soon. Feldman believes that what differentiates Rightway from traditional pharmacy benefit manager is its model. Feldman calls the traditional model a “taxi meter approach," with companies benefiting from members spending more on drugs, rather than focusing on customer experience. Feldman highlights Rightway's “pharmacist in the family approach,” that, according to Feldman, allows for greater customer assistance that ideally would ultimately allow members to make the right decision for their needs. “The pharmacy benefits space is at an inflection point,” insists Feldman, who sees sustainability only being possible if members are at the center. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Eyek Ntekim

  • Humana stock falls after reporting higher costs, dragging down other Medicare Advantage providers

    Humana (HUM) stock tumbled more than 12% on Thursday after the US health insurer reported an increase in older patients seeking care, which would hurt its fourth quarter results.

  • JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market

    Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.

  • Walgreens CEO: 'We don't need to own a health plan in order to create value'

    Walgreens CEO Tim Wentworth discussed the focus away from vertical integration at the JPMorgan healthcare conference in San Francisco.